JP7032428B2 - Ｍｃｌ－１阻害剤の合成 - Google Patents

Ｍｃｌ－１阻害剤の合成 Download PDF

Info

Publication number
JP7032428B2
JP7032428B2 JP2019552891A JP2019552891A JP7032428B2 JP 7032428 B2 JP7032428 B2 JP 7032428B2 JP 2019552891 A JP2019552891 A JP 2019552891A JP 2019552891 A JP2019552891 A JP 2019552891A JP 7032428 B2 JP7032428 B2 JP 7032428B2
Authority
JP
Japan
Prior art keywords
methyl
mol
pyrazole
solution
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019552891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515557A (ja
JP2020515557A5 (enExample
Inventor
クレイグ・ステュワート
サイモン・ハーディ
アンドリュー・スターク
アレクサンダー・ハード
チン・イェ
ジェン・シャオラン
カティ・フェラル
ヤン・クーク
デバシス・ハズラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2020515557A publication Critical patent/JP2020515557A/ja
Publication of JP2020515557A5 publication Critical patent/JP2020515557A5/ja
Application granted granted Critical
Publication of JP7032428B2 publication Critical patent/JP7032428B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/76—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2019552891A 2017-03-31 2018-03-29 Ｍｃｌ－１阻害剤の合成 Active JP7032428B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762479493P 2017-03-31 2017-03-31
US62/479,493 2017-03-31
PCT/EP2018/058056 WO2018178227A1 (en) 2017-03-31 2018-03-29 Synthesis of mcl-1 inhibitor

Publications (3)

Publication Number Publication Date
JP2020515557A JP2020515557A (ja) 2020-05-28
JP2020515557A5 JP2020515557A5 (enExample) 2021-03-11
JP7032428B2 true JP7032428B2 (ja) 2022-03-08

Family

ID=61827753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019552891A Active JP7032428B2 (ja) 2017-03-31 2018-03-29 Ｍｃｌ－１阻害剤の合成

Country Status (16)

Country Link
US (1) US11149024B2 (enExample)
EP (1) EP3601230B1 (enExample)
JP (1) JP7032428B2 (enExample)
KR (1) KR102604876B1 (enExample)
CN (1) CN110536884B (enExample)
AR (1) AR111304A1 (enExample)
AU (1) AU2018244180B2 (enExample)
CA (1) CA3056712A1 (enExample)
CO (1) CO2019010035A2 (enExample)
EA (1) EA038226B1 (enExample)
ES (1) ES2909751T3 (enExample)
IL (1) IL269410B2 (enExample)
MX (1) MX387814B (enExample)
TW (1) TWI781996B (enExample)
WO (1) WO2018178227A1 (enExample)
ZA (1) ZA201905645B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691989B2 (en) 2018-11-22 2023-07-04 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as Mcl-1 inhibitors
US12319703B2 (en) 2019-01-23 2025-06-03 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic fused pyrazoles as Mcl-1 inhibitors
KR20220024694A (ko) 2019-06-21 2022-03-03 얀센 파마슈티카 엔.브이. Mcl-1의 거대환식 억제제
WO2021005043A1 (en) 2019-07-09 2021-01-14 Janssen Pharmaceutica Nv Macrocyclic spirocycle derivatives as mcl-1 inhibitors
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2021099579A1 (en) 2019-11-21 2021-05-27 Janssen Pharmaceutica Nv Macrocyclic indole derivatives as mcl-1 inhibitors
MX2022006180A (es) 2019-11-21 2022-06-14 Janssen Pharmaceutica Nv Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
JP2023514364A (ja) 2020-02-21 2023-04-05 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１の阻害剤としての大環状インドール誘導体
EP4157852A1 (en) 2020-05-29 2023-04-05 JANSSEN Pharmaceutica NV Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1
MX2022015998A (es) * 2020-06-19 2023-04-12 Janssen Pharmaceutica Nv Derivados de 4-(pirazol-5-il)-indol macrocíclico unidos a n como inhibidores de mcl-1.
WO2021255257A1 (en) 2020-06-19 2021-12-23 Janssen Pharmaceutica Nv N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1
CA3184877A1 (en) 2020-07-08 2022-01-13 Benoit Christian Albert Ghislain De Boeck Macrocyclic ether containing indole derivatives as inhibitors of mcl-1
WO2022032284A1 (en) * 2020-08-07 2022-02-10 Zeno Management, Inc. Macrocyclic compounds
JP2023553719A (ja) 2020-12-17 2023-12-25 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１阻害剤としての分岐大環状４－（ピラゾール－５－イル）－インドール誘導体
JP2024506648A (ja) 2021-02-12 2024-02-14 ヤンセン ファーマシューティカ エヌ．ベー． がんの治療のためのｍｃｌ－１阻害剤としての大環状１，３－架橋６－クロロ－７－ピラゾール－４－イル－１ｈ－インドール－２－カルボキシレート及び６－クロロ－７－ピリミジン－５－イル－１ｈ－インドール－２－カルボキシレート誘導体
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160106731A1 (en) 2014-10-17 2016-04-21 Vanderbilt University Tricyclic indole mcl-1 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2915811A1 (en) * 2014-03-04 2015-09-09 Centre Régional de Lutte contre le Cancer - Centre François Baclesse MCL-1 modulating compounds for cancer treatment
CN105061315B (zh) * 2015-08-06 2017-10-24 大连理工大学 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用
MX386103B (es) * 2016-04-22 2025-03-18 Astrazeneca Ab Inhibidores de mcl-1 y metodos de uso de los mismos.
CN106478606B (zh) * 2016-09-21 2019-05-10 沈阳药科大学 N-取代吲哚类衍生物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160106731A1 (en) 2014-10-17 2016-04-21 Vanderbilt University Tricyclic indole mcl-1 inhibitors and uses thereof

Also Published As

Publication number Publication date
BR112019019686A2 (pt) 2020-04-14
CA3056712A1 (en) 2018-10-04
CO2019010035A2 (es) 2019-09-30
US20210122735A1 (en) 2021-04-29
IL269410A (en) 2019-11-28
ZA201905645B (en) 2020-05-27
KR102604876B1 (ko) 2023-11-22
EA201992235A1 (ru) 2020-02-10
MX2019011468A (es) 2019-11-01
AU2018244180A1 (en) 2019-11-07
TW201902868A (zh) 2019-01-16
KR20190136039A (ko) 2019-12-09
CN110536884A (zh) 2019-12-03
TWI781996B (zh) 2022-11-01
AR111304A1 (es) 2019-06-26
EP3601230A1 (en) 2020-02-05
EP3601230B1 (en) 2022-01-26
EA038226B1 (ru) 2021-07-27
JP2020515557A (ja) 2020-05-28
IL269410B2 (en) 2023-03-01
CN110536884B (zh) 2023-05-02
WO2018178227A1 (en) 2018-10-04
ES2909751T3 (es) 2022-05-10
MX387814B (es) 2025-03-04
US11149024B2 (en) 2021-10-19
AU2018244180B2 (en) 2021-03-04
IL269410B (en) 2022-11-01

Similar Documents

Publication Publication Date Title
JP7032428B2 (ja) Ｍｃｌ－１阻害剤の合成
KR101593253B1 (ko) 페닐 및 벤조디옥시닐 치환 인다졸 유도체
JP7769066B2 (ja) （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの製造方法及び中間体
KR20230096973A (ko) Jak 저해제를 제조하기 위한 방법 및 중간체
WO2019141131A1 (zh) 溴结构域抑制剂化合物及其用途
WO2016035847A1 (ja) セファロスポリン誘導体の中間体およびその製造方法
WO2014017516A1 (ja) ４－［５－（ピリジン－４－イル）－１ｈ－１，２，４－トリアゾール－３－イル］ピリジン－２－カルボニトリルの製造方法および中間体
JP2023520396A (ja) アルファ１－アンチトリプシンのモジュレーター
WO2018126898A1 (zh) 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
US20060058370A1 (en) Methods for producing cyclic benzamidine derivatives
JP2020535193A (ja) 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス
JP2024501554A (ja) オキシスピロ環置換ピロロピラゾール誘導体及びその中間体並びにその調製方法
JP2025538526A (ja) ピリミジンアミノピラゾール化合物を調製するためのプロセス及び中間体
HK40013365A (en) Synthesis of mcl-1 inhibitor
HK40013365B (en) Synthesis of mcl-1 inhibitor
JP2025518342A (ja) ベンゾ［ｃ］クロマン化合物の多形、その製造方法、及びその使用
BR112019019686B1 (pt) Compostos selecionados para síntese de inibidor de mcl-1
HK40022816B (en) Synthesis of mcl-1 inhibitor
HK40022816A (en) Synthesis of mcl-1 inhibitor
CN108424417B (zh) 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
WO2018133159A1 (zh) 一类喹啉类新化合物制备方法
WO2021213111A1 (zh) Snail抑制剂及其衍生物，制备方法、药物组合物和应用
JP2020535192A (ja) レナリドミドの結晶形
CN110759923B (zh) 嘧啶并吡咯并哒嗪衍生物、其中间体、制备方法、药物组合物和用途
WO2024048615A1 (ja) キノキサリン誘導体の製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220224

R150 Certificate of patent or registration of utility model

Ref document number: 7032428

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250